Daiichi Sankyo Trials Triple Therapy for Coronary Atherosclerosis Without Events
The trial evaluates a triple therapy of bempedoic acid, ezetimibe, and high-intensity statins on coronary plaque in patients without prior ischemic events.
Asset / Drug
Drug and asset intelligence for Daiichi with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.